Pfizer RSV Vaccine Protection Wanes Over Three Seasons
A retrospective study of nursing home residents found RSVpreF's protection against lab-confirmed RSV declined from the first to the third season.
Updated on Nov. 12, 2026 in COVID-19

Live Poll
Would you get an RSV booster if doctors recommended one for older adults?
A retrospective cohort study of 23,050 nursing home residents found that Pfizer's bivalent RSVpreF vaccine was associated with a meaningful reduction in RSV risk, but protection weakened across the October 2023 to April 2026 seasons assessed. Of 312 laboratory-confirmed RSV cases, 241 (77%) occurred among nonvaccinated residents.
Why it matters
The decline in vaccine effectiveness over successive seasons raises questions about when and for whom revaccination may be warranted. Understanding protection beyond three seasons is considered important for informing those decisions.
The study compared vaccine effectiveness across three seasons, with 70.2% in the first, 52.8% in the second and 33.1% in the third, against the phase 3 trial efficacy of 66.7% for RSV lower respiratory illness and 85.7% for severe illness. Protection beyond three seasons has not been characterized in this analysis.
The players
Pfizer
Pfizer is a multinational pharmaceutical company that developed the RSVpreF vaccine, which was approved in 2023 based on a phase 3 trial among adults aged 60 years or older.
The details
Researchers assessed 23,050 nursing home residents, following 5,187 of them across multiple seasons, and identified 312 laboratory-confirmed RSV infections. Of the breakthrough cases among vaccinated residents, 20 (28%) occurred in the first season and 51 (72%) in the second or third seasons.
Timeline
October 2023 to April 2024: first RSV season assessed
October 2024 to April 2025: second RSV season assessed
October 2025 to April 2026: third RSV season assessed
Health Landscape
The study extends the efficacy figures from the RSVpreF phase 3 trial that supported its 2023 approval for adults aged 60 and older, showing how protection in nursing homes declined across three seasons. It adds real-world evidence to a vaccine whose trial results were reported before multi-season data existed.
Nursing home residents and their caregivers may need to consider how long RSVpreF protection lasts when deciding on timing of vaccination. The study's findings suggest protection declined markedly over three seasons, though decisions about revaccination remain under review.
The takeaway
Vaccine protection against RSV in older adults may not remain at its initial level across multiple seasons. Readers should discuss timing and revaccination questions with their healthcare providers.
Further reading
For related coverage, see COVID-19 reporting in the United States section.
Source note: This article includes information reported by Healio.
Live Poll
Would you get an RSV booster if doctors recommended one for older adults?










